These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8518223)

  • 21. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
    J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer.
    Muss HB; Lokich JJ; Frei E
    Clin Pharmacol Ther; 1975 Aug; 18(2):234-7. PubMed ID: 1149369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
    Scheithauer W; Depisch D; Kornek G; Pidlich J; Rosen H; Karall M; Prochaska M; Ernst A; Sebesta C; Eckhardt S
    Cancer; 1994 Mar; 73(6):1562-8. PubMed ID: 8156482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
    Vaudo CE; Gil B; Galuski K; Zarwan C; Nugent FW
    Pharmacotherapy; 2016 Nov; 36(11):e178-e182. PubMed ID: 27716991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
    Schmoll HJ; Köhne-Wömpner CH; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann HP; Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):191-6. PubMed ID: 1557646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
    Konishi K; Yabushita K; Taguchi T; Ota J; Takashima S; Abe T; Kikkawa N; Yasutomi M; Sowa M; Maehara Y
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):925-32. PubMed ID: 7793998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats.
    Umezawa T; Kiba T; Numata K; Saito T; Nakaoka M; Shintani S; Sekihara H
    Anticancer Res; 2000; 20(6B):4235-42. PubMed ID: 11205253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
    Stöger H; Bauernhofer T; Schmid M; Ploner F; Moser R; Derstvenscheg E; Steindorfer P; Wilders-Truschnig M; Kuss I; Samonigg H
    Cancer Chemother Pharmacol; 1994; 35(2):174-8. PubMed ID: 7987997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
    Lokich JJ; Pitman SW; Skarin AT
    Oncology; 1975; 32(1):34-7. PubMed ID: 1208028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and pharmacologic study of orally administered uridine.
    van Groeningen CJ; Peters GJ; Nadal JC; Laurensse E; Pinedo HM
    J Natl Cancer Inst; 1991 Mar; 83(6):437-41. PubMed ID: 1999851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B; Singh G; Silberman H
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.